The cost‐effectiveness of dapagliflozin compared to DPP‐4 inhibitors in the treatment of type 2 diabetes mellitus in the Netherlands

N. Van der Linden, S. Van Olst, S. Nekeman, C.A. Uyl-de Groot

Research output: Contribution to journalArticleAcademicpeer-review

2 Downloads (Pure)
Original languageEnglish
Article numbere14371
JournalDiabetic medicine
Issue number4
Publication statusPublished - 18 Apr 2021
Externally publishedYes

Cite this